Skip to main content
Erschienen in: General Thoracic and Cardiovascular Surgery Cases 1/2023

Open Access 01.12.2023 | Case Report

Successful surgical treatment for primary cardiac angiosarcoma: a case report

verfasst von: Yasuo Suehiro, Tetsuya Kajiyama, Ayaka Satoh, Hisashi Uemura, Takaya Nakagawa, Hajime Matsue, Hisashi Satoh, Naoto Takase, Hiroshi Doi

Erschienen in: General Thoracic and Cardiovascular Surgery Cases | Ausgabe 1/2023

Abstract

Background

Primary cardiac angiosarcomas are extremely rare and their prognosis is poor. Surgical resection is the first-line treatment; however, no clear standard of care has been clearly established because of the rarity of these tumors.

Case presentation

A 61-year-old man who had presented with dyspnea on exertion was referred to our hospital. Contrast-enhanced computed tomography revealed massive pericardial effusion and a 40-mm enhanced mass adherent to the anterior wall of the right atrium and involving the right coronary artery. Having diagnosed the mass as a cardiac tumor, we resected the mass under the guidance of epi-cardiac echocardiography guidance, which showed continuity between the tumor and the right atrium, reconstructed the right atrial free wall with a bovine pericardial patch, and performed coronary artery bypass grafting to the right coronary artery using the great saphenous vein. The right atrial wall was resected with adequate tumor-free margin. On the right ventricular side, we resected the right atrial wall 1 cm from the tumor, 2 cm from the atrioventricular groove. Because hemodynamic deterioration occurred after aortic declamping, intra-aortic balloon pumping and veno-arterial extracorporeal membrane oxygenation were instituted. Postoperatively, circulatory support devices were removed safely, and the patient was discharged on the 25th postoperative day. Histopathological examination of the surgical specimens resulted in a diagnosis of angiosarcoma, with positive surgical margins. Chemotherapy and radiotherapy (69 Gy in 30 fractions) were therefore initiated after discharge. To date, the patient has been alive and well with no recurrence of tumor for 4 years and 10 months since surgery.

Discussion

This case study suggests the usefulness of multimodality treatment comprising surgical resection and adjuvant therapy, for cardiac angiosarcoma.
Hinweise
The original version of this article was revised: two authors have to be added to the published article upon editorial approval. It was: Yasuo Suehiro1*, Tetsuya Kajiyama2, Ayaka Satoh1, Hisashi Uemura1, Takaya Nakagawa1, Hajime Matsue1 and Hisashi Satoh1. It should be: Yasuo Suehiro1*, Tetsuya Kajiyama2, Ayaka Satoh1, Hisashi Uemura1, Takaya Nakagawa1, Hajime Matsue1 and Hisashi Satoh1, Naoto Takase 3, Hiroshi Doi 4.
A correction to this article is available online at https://​doi.​org/​10.​1186/​s44215-024-00127-9.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
CT
Computed tomography
RCA
Right coronary artery
MRI
Magnetic resonance imaging

Background

Primary cardiac angiosarcomas are rare, highly malignant tumors with a poor prognosis. The diagnosis is often delayed because many patients remain asymptomatic. While surgical resection is the gold standard for treatment, adjuvant therapy is also reportedly effective. Additionally, combination therapy is considered to increase survival. We herein report a case of right atrial angiosarcoma successfully treated with surgical resection and postoperative chemoradiation therapy.

Case presentation

A 61-year-old man without significant medical history who had presented with dyspnea on exertion was referred to our department for evaluation of a cardiac mass and massive pericardial effusion on computed tomography (CT) images. On admission, physical examinations revealed no abnormal findings, blood pressure of 120/80 mm of mercury, and heart rate of 76 beats per minute. Percutaneous oxygen saturation was 94% at rest in room air, which was slightly decreased compared with normal. Transthoracic echocardiography showed a tumor adjacent to the right atrium and massive pericardial effusion with features of cardiac tamponade. Contrast-enhanced CT revealed a 40-mm hypervascular mass adherent to the anterior wall of the right atrium and involving the right coronary artery (RCA). Magnetic resonance imaging (MRI) also showed this mass at the same location, which exhibited isointense to high signal intensity on T2-weighted images (Fig. 1). No metastasis was confirmed with imaging. Laboratory tests revealed a mildly elevated serum level of C-reactive protein concentration of 3.6 mg/L. Based on these findings, we made a provisional diagnosis of cardiac angiosarcoma arising in the right atrium and scheduled its resection.
The procedure was performed through a median sternotomy. A hemorrhagic pericardial effusion and hard mass elastic protruding from the anterior wall of the right atrium were noted intraoperatively. Cardiopulmonary bypass was established after the ascending aorta, superior vena cava, and inferior vena had been cannulated. Cardiac arrest was accomplished with blood cardioplegia. Under the guidance of epi-cardiac echo images of the extent of the tumor and continuity between the tumor and the right atrium, we macroscopically achieved complete resection of the tumor together with the right atrial free wall and RCA. The right atrial wall was resected with adequate tumor-free margins. On the right ventricular side, we resected the right atrial wall 1 cm form the tumor and 2 cm from the atrioventricular groove. We then reconstructed the right atrial free wall with a bovine pericardial patch and performed coronary artery bypass grafting to the RCA using the great saphenous vein (Fig. 2). Because hemodynamic deterioration caused by sacrifice of the right ventricular branches occurred after aortic declamping, intra-aortic balloon pumping and veno-arterial extracorporeal membrane oxygenation were instituted.
Pathological examination of the resected specimen revealed fusiform tumor cells, frequent mitoses, and a vascular neoformation with intramural red blood cells (Fig. 3), resulting in a diagnosis of primary cardiac angiosarcoma. Resection was incomplete, as shown by positive surgical margins.
Postoperatively, veno-arterial extracorporeal membrane oxygenation and intra-aortic balloon pumping were removed safely on the 2nd and 7th postoperative day, respectively. The patient was discharged on the 25th postoperative day. Chemotherapy for 9 weeks with weekly paclitaxel 80 mg/m2 and radiotherapy for 48 days (69 Gy in 30 fractions using intensity modulated radiotherapy) were initiated on the 64th postoperative day. To date, the patient remains alive and well with no recurrence of tumor for 4 years and 10 months postoperatively.

Discussion

Primary cardiac tumors are extremely rare, with an autopsy incidence ranging from 0.001–0.28%. Approximately 25% of cardiac tumors are malignant, cardiac angiosarcomas are the commonest of these, accounting for 30% [1, 2]. Seventy percent of cardiac angiosarcomas arise in the right atrium [3], and metastases are present at the time of diagnosis in approximately 66–89% of cases [4]. Angiosarcomas have a poor prognosis, with a mean survival of 6 months. Furthermore, even in surgically-treated cases, survival time after surgery is likely to be within 10 months [1]. Because many patients remain asymptomatic until the tumor reaches a certain size, diagnosis is often delayed.
Imaging tests, such as echocardiography, CT, MRI, and fluorodeoxyglucose-positron emission tomography, are helpful for the detection and accurate diagnosis of cardiac tumors. Such imaging can provide us information about the presence of both a tumor and metastases, as well as the relationship between the tumor and the surrounding structures. Contrast-enhanced CT shows heterogeneous enhancement and MRI shows heterogeneous T2-weightned signal intensity patterns, as in the present case. Histopathology is necessary for a definitive diagnosis, pericardial fluid cytology having a low diagnostic yield [4]. Because needle biopsy carries risks of bleeding and inducing metastatic spread, it may be preferable to obtaining a specimen surgically.
Resection is the standard first-line treatment for cardiac angiosarcomas. Hamidi et al. reported that the median survival of those who undergo surgery is 12 months, whereas survival is 1 month for those who do not [5]. According to Bakaeen et al., complete resection of these tumors achieves better overall survival than does incomplete resection [6]. When the tumor is large, early surgical intervention is recommended because of concerns regarding intra-cardiac obstruction by the tumor, and occasionally incarceration, of the tumor.
In the present case, after the tumor had been confirmed by epi-cardiac echo intraoperatively to have continuity with the right atrium, we macroscopically achieved complete resection of the right atrial free wall along with the tumor. However, histopathological examination revealed positive margins on the side of the right ventricle. If we had tried to achieve adequate tumor-free margins, reconstruction of the right ventricle and tricuspid valve would have been necessary. When deciding on the extent of resection, surgeons must consider the feasibility and difficulty of reconstructing cardiac structures and the procedure’s disadvantages, including prolonged cardiac arrest time.
Chemotherapy and radiotherapy are the most commonly used forms of adjuvant therapy for angiosarcomas; however, their benefits are controversial because of the rarity of these tumors. Luk, A. et al. reported the efficacy of postoperative chemotherapy, radiotherapy, or a combination of these [7]. Furthermore, patients treated by complete resection alone characteristically rapidly develop metastases postoperatively [8], whereas some who undergo complete resection and postoperative chemoradiation therapy do not develop recurrences thereafter [9, 10], even in cases of negative surgical margins.
The traditional chemotherapy drugs for angiosarcoma are anthracycline, ifosfamide, and taxanes (paclitaxel and docetaxel). Recently, taxanes have displayed good efficacy as adjuvant chemotherapy [11], and in particular, weekly paclitaxel has demonstrated clinical benefit [12]. Regarding the radiotherapy, National Comprehensive Cancer Network guideline recommends over 70 Gy of external beam radiotherapy as definitive treatment of unresectable soft tissue sarcomas [13]. The safety and efficacy of this treatment regimen of intensity modulated radiotherapy using the simultaneous integrated boost technique for sarcomas have been reported [14, 15]. Besides, combination of weekly paclitaxel and radiotherapy is reportedly more effective for cardiac angiosarcoma [16], as described in the present case. We believe that postoperative adjuvant therapy is warranted regardless of whether complete resection is achieved. Heart transplantation is a possible therapeutic option, but too few patients have undergone this treatment to allow assessment of its survival benefit.

Conclusion

We presented a case of right atrial angiosarcoma successfully treated with surgical resection and postoperative chemoradiation therapy. Achieving complete resection is the most important prognostic factor. We believe that multimodality approaches comprising surgery and adjuvant therapy are crucial for improving overall survival.

Acknowledgements

We thank Dr. Trish Reynolds, MBBS, FRACP and Janes Charbonneau, DVM, from Edanz (http://​jp.​edanz.​com/​ac) for editing a draft for this manuscript.

Declarations

No applicable.
Written informed consent was obtained from the patient for publication of the case report and accompanying images.

Competing interests

The authors declare that they have no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
2.
Zurück zum Zitat Dennig K, Lehmann G, Richter T. An angiosarcoma in the left atrium. N Engl J Med. 2000;342:443–4.CrossRefPubMed Dennig K, Lehmann G, Richter T. An angiosarcoma in the left atrium. N Engl J Med. 2000;342:443–4.CrossRefPubMed
3.
Zurück zum Zitat Rettmar K, Stierle U, Sheikhzadeh A, Diederich KW. Primary angiosarcoma of the heart. Report of a case and review of the literature. Jpn Heart J. 1993;34:667–83.CrossRefPubMed Rettmar K, Stierle U, Sheikhzadeh A, Diederich KW. Primary angiosarcoma of the heart. Report of a case and review of the literature. Jpn Heart J. 1993;34:667–83.CrossRefPubMed
4.
6.
Zurück zum Zitat Bakaeen FG, Jaroszewski DE, Rice DC, Walsh GL, Vaporciyan AA, Swisher SS, et al. Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era. J Thorac Cardiovasc Surg. 2009;137:1454–60.CrossRefPubMed Bakaeen FG, Jaroszewski DE, Rice DC, Walsh GL, Vaporciyan AA, Swisher SS, et al. Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era. J Thorac Cardiovasc Surg. 2009;137:1454–60.CrossRefPubMed
7.
Zurück zum Zitat Luk A, Nwachunkwu H, Lim KD, Cusimano RJ, Butany J. Cardiac angiosarcoma: a case report and review of the literature. Cardiovasc Pathol. 2010;19:69–74.CrossRef Luk A, Nwachunkwu H, Lim KD, Cusimano RJ, Butany J. Cardiac angiosarcoma: a case report and review of the literature. Cardiovasc Pathol. 2010;19:69–74.CrossRef
8.
Zurück zum Zitat Yada M, Tara Y, Sato S, Sekine Y, Nishina T, Yamanaka K, et al. A case of primary cardiac angiosarcoma with surgical resection and reconstruction. J Cardiol Cases. 2021;25:103–5.CrossRefPubMedPubMedCentral Yada M, Tara Y, Sato S, Sekine Y, Nishina T, Yamanaka K, et al. A case of primary cardiac angiosarcoma with surgical resection and reconstruction. J Cardiol Cases. 2021;25:103–5.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Nakamichi T, Fukuda T, Suzuki T, Kaneko T, Morikawa Y. Primary cardiac angiosarcoma: 53 Months’ survival after multidisciplinary therapy. Ann Thorac Surg. 1997;63:1160–1.CrossRefPubMed Nakamichi T, Fukuda T, Suzuki T, Kaneko T, Morikawa Y. Primary cardiac angiosarcoma: 53 Months’ survival after multidisciplinary therapy. Ann Thorac Surg. 1997;63:1160–1.CrossRefPubMed
10.
11.
Zurück zum Zitat Kajihara I, Kanemaru H, Miyake T, Aoi J, Masuguchi S, Fukushima S, et al. Combination chemotherapy with S-1 and docetaxel for cutaneous angiosarcoma resistant to paclitaxel. Drug Discov Ther. 2015;9:75–7.CrossRefPubMed Kajihara I, Kanemaru H, Miyake T, Aoi J, Masuguchi S, Fukushima S, et al. Combination chemotherapy with S-1 and docetaxel for cutaneous angiosarcoma resistant to paclitaxel. Drug Discov Ther. 2015;9:75–7.CrossRefPubMed
12.
Zurück zum Zitat Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26:5269–74.CrossRefPubMed Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26:5269–74.CrossRefPubMed
13.
Zurück zum Zitat National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. 2022. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. 2022.
14.
Zurück zum Zitat Fujiwara M, Doi H, Igeta M, Suzuki H, Kitajima K, Tanooka M, et al. Radiation pneumonitis after volumetric modulated arc therapy for non-small cell lung cancer. Anticancer Res. 2021;41:5793–802.CrossRefPubMed Fujiwara M, Doi H, Igeta M, Suzuki H, Kitajima K, Tanooka M, et al. Radiation pneumonitis after volumetric modulated arc therapy for non-small cell lung cancer. Anticancer Res. 2021;41:5793–802.CrossRefPubMed
15.
Zurück zum Zitat Doi H, Oh RJ, Miura H, Masai N, Shiomi H, Inoue T. Outcomes and toxicity of radiotherapy for refractory bone and soft tissue sarcomas. Mol Clin Oncol. 2016;4:83–8.CrossRefPubMed Doi H, Oh RJ, Miura H, Masai N, Shiomi H, Inoue T. Outcomes and toxicity of radiotherapy for refractory bone and soft tissue sarcomas. Mol Clin Oncol. 2016;4:83–8.CrossRefPubMed
16.
Zurück zum Zitat Roy A, Gabani P, Davis EJ, Oppelt P, Merfeld E, Keedy VL, et al. Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma. Clin Transl Radiat Oncol. 2021;27:114–20.PubMedPubMedCentral Roy A, Gabani P, Davis EJ, Oppelt P, Merfeld E, Keedy VL, et al. Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma. Clin Transl Radiat Oncol. 2021;27:114–20.PubMedPubMedCentral
Metadaten
Titel
Successful surgical treatment for primary cardiac angiosarcoma: a case report
verfasst von
Yasuo Suehiro
Tetsuya Kajiyama
Ayaka Satoh
Hisashi Uemura
Takaya Nakagawa
Hajime Matsue
Hisashi Satoh
Naoto Takase
Hiroshi Doi
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
General Thoracic and Cardiovascular Surgery Cases / Ausgabe 1/2023
Elektronische ISSN: 2731-6203
DOI
https://doi.org/10.1186/s44215-023-00119-1

Weitere Artikel der Ausgabe 1/2023

General Thoracic and Cardiovascular Surgery Cases 1/2023 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.